Navigation Links
Prolong Pharmaceuticals Boosts Executive Team

SOUTH PLAINFIELD, N.J., Nov. 18, 2010 /PRNewswire/ -- Prolong Pharmaceuticals, which last month announced a $30 million funding commitment from a private investor group, today announced the formal addition of two pharmaceutical veterans to its senior management team. Richard Prince is now Vice President, Quality and Andy Burger has assumed the title of Vice President, Information Services.

"Both Richard and Andy bring solid industry experience plus a history of cutting edge, out-of the-box thinking to pharmaceutical development," said Prolong President Glenn Kazo. "Since we are already producing biological product in a cGMP environment, with several stages of scale-up necessary prior to commercial launch, product quality and data integrity are fundamental to our business success.  We are pleased to have each of these key areas led by seasoned veterans who are excited about our corporate mission," added Kazo.

Dr. Prince, a microbiologist by training, possesses a multi-faceted background in the bio/pharmaceutical industry, with more than 25 years of experience in large Pharma, several start-ups, and as a quality consultant across the industry. Well regarded as a leader in the areas of quality management, validation, regulatory compliance, and laboratory operations, Prince has published four textbooks with the Parenteral Drug Association press.  "I joined Prolong because management views the Quality function as a strategic business asset designed to build and maintain a robust Quality System used to establish and make accountable a GMP-compliant manufacturing operation," stated Dr. Prince.  

As a 27-year industry veteran, for the past 13 years in the pharmaceutical industry, Burger has held executive titles, including Chief Information Officer, providing global technology initiatives, FDA-based compliance services, and multiple merger/acquisition coordination efforts.  Prior to venturing into the pharmaceutical industry, Andy was at the forefront of the wireless telecommunications industry, both as General Manager, Technology Development for Bell Atlantic Mobile (Verizon Wireless), and Chief IT Architect for Omnipoint Communications (t-Mobile USA).  "By developing an industry hardened yet agile enterprise architecture data model at this early stage of our production operations, we are providing accountability, transparency, and full regulatory control to all data dependent aspects of our operations, computing platforms, and our products from raw materials to the final lot numbered assets," stated Burger.

Prolong's CEO, Dr. Abraham Abuchowski, said that Burger and Prince were part of a calculated business model to create a management team capable of the rapid and cost-effective approval of major products. "We are building a new kind of biopharmaceutical model," said Abuchowski. "Simply put, drug development in the U.S. takes too long and costs too much money, and much of that inefficiency is due to poor planning and management control. We are taking a proactive rather than reactive approach and will have each piece of our quality, regulatory, manufacturing and IT pieces in place and ready to go as needed."   

About Prolong Pharmaceuticals

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company, Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit:

SOURCE Prolong Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolong Pharmaceuticals Secures $30 Million in Funding
2. Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President
3. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
4. Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases
5. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
6. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
9. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
10. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
11. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
Post Your Comments:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):